-
Product Insights
NewLikelihood of Approval Analysis for Sezary Syndrome
Overview How likely is it that the drugs in Sezary Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sezary Syndrome Overview Sezary syndrome is an erythrodermic cutaneous T-cell lymphoma with...
-
Product Insights
NewLikelihood of Approval Analysis for Cholestasis
Overview How likely is it that the drugs in Cholestasis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cholestasis Overview Cholestasis is the slowing or stalling of bile flow from liver....
-
Product Insights
NewSouth Jambi B
Empower your strategies with our South Jambi B Field, Indonesia report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain a gateway to actionable insights and competitive advantage. Acquire a thorough understanding of...
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
NewChina Beverages Consumption Trends and Forecasts Tracker, Q4 2023
China Beverages Market Report Overview The China beverages market size was valued at 99.423 billion liters (BL) in Q4 2023. The China beverages market research report has recorded essential data on key products, their categories, and their consumption volume in the country for Q4 2023. Furthermore, the report precisely lists new product launches and highlights the latest beverage industry performance and developments every quarter. Buy the Full Report for More Insights on the China Beverages Market Forecast Download a Free...
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Maplirpacept
Empower your strategies with our Net Present Value Model: Pfizer Inc's Maplirpacept report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novo Nordisk AS’s Cagrisema
Empower your strategies with our Net Present Value Model: Novo Nordisk AS's Cagrisema report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Kinnate Biopharma Inc’s Exarafenib
Empower your strategies with our Net Present Value Model: Kinnate Biopharma Inc's Exarafenib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Sanofi’s Fitusiran
Empower your strategies with our Net Present Value Model: Sanofi's Fitusiran report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Saruparib
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Saruparib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.